Impact Factor ISSN: 1837-9664
Research Paper Bevacizumab or Aflibercept in Combination with Second-Line FOLFIRI after Progression on FOLFOX Plus Bevacizumab in Metastatic Colorectal Cancer: A Comparative Study Full text PDF
Review Urine-derived induced pluripotent stem cells for non-invasive diagnosis of bladder cancer Full text PDF
Research Paper Associations of HMGA2 single-nucleotide polymorphisms with clinicopathological features of tongue squamous cell carcinoma in Taiwanese men with distinct lifestyle-related risk factors Full text PDF
Research Paper Separability of histopathology foundation model embeddings of stimulated Raman histology images for lung carcinoma subtyping Full text PDF
Review Advances in CAR-T Cell Therapy: From Structural Design Innovations to Clinical Translation Challenges Full text PDF PubMed PMC
Review Regulatory roles of E3 ubiquitin ligase RNF128 in inflammatory diseases and tumors Full text PDF PubMed PMC
Issue 9; 2026
Indexed in PubMed and SCI expanded; full texts in Europe PMC. ...
Background: The optimal anti-angiogenic strategy in the second-line treatment of metastatic colorectal cancer (mCRC) after progression on first-line FOLFOX plus bevacizumab remains unclear. We aimed to compare the efficacy and safety of FOLFIRI combined with bevacizumab or aflibercept in this well-defined clinical setting. Methods: In this retrospective single-center study, 152 patients with mCRC who progressed after at least four cycles of first-line ...
Urine-derived induced pluripotent stem cells for non-invasive diagnosis of bladder cancer
Bladder cancer (BLCA) remains one of the most prevalent and costly malignancies worldwide, largely owing to its high recurrence rate and the invasive nature of conventional surveillance modalities. Induced pluripotent stem cell (iPSC) technology offers a new framework for disease modeling and, potentially, precision diagnostics. Urine provides a non-invasive, renewable source of exfoliated urothelial and renal epithelial cells amenable to direct reprogramming. ...